E-LIB Suche - Ergebnisse für: Seymour, John F.

1

Six-year follow-up and subgroup analyses of a phase 2 trial..:

Stilgenbauer, Stephan ; Tausch, Eugen ; Roberts, Andrew W....
Blood Advances. 8 (2024) 8 - p. 1992-2004 , 2024

Link: https://doi.org/10.1182/..

2

Venetoclax Initiation in Chronic Lymphocytic Leukemia: Inte..:

Anderson, Mary Ann ; Walewska, Renata ; Hackett, Fidelma...
Cancers. 16 (2024) 5 - p. 980 , 2024

Link: https://doi.org/10.3390/..

3

Mutational profile of previously treated chronic lymphocyti..:

Woyach, Jennifer A. ; Jones, Daniel ; Jurczak, Wojciech...
Blood Journal. , 2024

Link: https://doi.org/10.1182/..

4

Primary gastric diffuse large B‐cell lymphoma: A multicentr..:

Lewis, Cameron S. ; Joy, Greta ; Jensen, Paw...
British Journal of Haematology. , 2024

Link: https://doi.org/10.1111/..

5

Venetoclax-rituximab is active in patients with BTKi-expose..:

Lew, Thomas E. ; Bennett, Rory ; Lin, Victor S....
Blood Advances. 8 (2024) 6 - p. 1439-1443 , 2024

Link: https://doi.org/10.1182/..

6

Update on the management of relapsed/refractory chronic lym..:

Bennett, Rory ; Seymour, John F.
Blood Cancer Journal. 14 (2024) 1 - p. , 2024

Link: https://doi.org/10.1038/..

7

Analysis of ventricular arrhythmias and sudden death from p..:

Sharman, Jeff P. ; Ghia, Paolo ; Miranda, Paulo...
British Journal of Haematology. , 2024

Link: https://doi.org/10.1111/..

8

CD34‐TdT‐B‐ALL masquerading as Burkitt lymphoma:

Juneja, Manu ; Wei, Andrew ; Mason, Kylie...
eJHaem. 5 (2024) 3 - p. 631-632 , 2024

Link: https://doi.org/10.1002/..

9

Polatuzumab vedotin, venetoclax, and an anti‐CD20 monoclona..:

Yuen, Sam ; Phillips, Tycel J. ; Bannerji, Rajat...
American Journal of Hematology. 99 (2024) 7 - p. 1281-1289 , 2024

Link: https://doi.org/10.1002/..

10

A systematic review and meta‐analysis of the impacts of ger..:

Lingaratnam, Senthil ; Shah, Mahek ; Nicolazzo, Joseph...
Clinical and Translational Science. 17 (2024) 5 - p. , 2024

Link: https://doi.org/10.1111/..

11

Evolution of Humoral and Cellular Immunity Post–Breakthroug..:

Hall, Victoria G ; Nguyen, Thi H O ; Allen, Lilith F...
Open Forum Infectious Diseases. 10 (2023) 11 - p. , 2023

Link: https://doi.org/10.1093/..

12

Approach to relapsed CLL including Richter Transformation:

Seymour, John F.
Hematological Oncology. 41 (2023) S1 - p. 136-143 , 2023

Link: https://doi.org/10.1002/..

13

S201: FINAL 7-YEAR FOLLOW UP AND RETREATMENT SUBSTUDY ANALY..:

Kater, Arnon ; Harrup, Rosemary ; Kipps, Thomas J...
HemaSphere. 7 (2023) S3 - p. e492813f , 2023

Link: https://doi.org/10.1097/..

14

POSTER: CLL-194 Ibrutinib for Treatment of Relapsed-Refract..:

Burger, Jan ; Ghia, Paolo ; Munir, Talha...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) - p. S173 , 2023

Link: https://doi.org/10.1016/..

15

Favorable outcomes of DDX41‐mutated myelodysplastic syndrom..:

Tiong, Ing S. ; Stevenson, William S. ; Wall, Meaghan...
eJHaem. 4 (2023) 4 - p. 1212-1215 , 2023

Link: https://doi.org/10.1002/..